This is supported by a recent study investigating the switch from Gla-100 to Gla-300 in real-life practice [42], in which people with T1DM experienced similar glycemic control and less nocturnal hypoglycemia in the 2 weeks after switching vs. the 2 weeks before switching, despite a slight increase (~ 1 – 2 U/day) in basal insulin dose. The gene discussed is INS; the disease is Hypoglycemia.